Thrombopoietin in the treatment of acute myeloid leukemia and in stem- cell transplantation

Seminars in Hematology

Volumn 37, Issue 2 SUPPL. 4, 2000, Pages 35-40

  Linker, Charles ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; CYTARABINE; CYTOKINE RECEPTOR; DAUNORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; PLACEBO; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT THROMBOPOIETIN; THROMBOPOIETIN;

ACUTE GRANULOCYTIC LEUKEMIA; BIOLOGICAL THERAPY; BLEEDING; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SOLID TUMOR; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 0034127783     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0037-1963(00)90051-9     Document Type: Review

References (21)

1. P Anderlini M Luna HM Kantarjian Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes Leukemia 10 1996 600 608
2. E Tornebohm D Lockner C Paul A retrospective analysis of bleeding complications in 438 patients with acute leukaemia during the years 1972–1991 Eur J Haematol 50 1993 160 167
3. J Gmur J Burger U Schanz Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia Lancet 338 1991 1223 1226
4. C Sarkodee-Adoo CA Schiffer Platelet transfusion support for patients with cancer and hematologic malignancies Curr Opin Hematol 3 1996 347 354
5. K Kaushansky Thrombopoietin: Understanding and manipulating platelet production Annu Rev Med 48 1997 1 11
6. S Vadhan-Raj S Patel HE Broxmeyer Phase I–II investigation of recombinant human thrombopoietin (rhTPO) in patients with sarcoma receiving high dose chemotherapy (CT) with Adriamycin (A) and ifosfamide (I) Blood 88 suppl 1 1996 448a abstr 1779
7. RL Basser JE Rasko K Clarke Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer Blood 89 1997 3118 3128
8. RL Basser JE Rasko K Clarke Erratum Blood 90 1997 2513
9. J Crawford J Glaspy C Belani A randomized, placebo-controlled, blinded, dose scheduling trial of pegylated recombinant human megakaryocyte growth and development factor (PEG-RHUMGDF) with filgrastim support in non-small cell lung cancer (NSCLC) patients treated with paclitaxel and carboplatin during multiple cycle of chemotherapy Proc Am Soc Clin Oncol 17 1998 73a (suppl 1, abstr 285)
10. M Fanucchi J Glaspy J Crawford Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer N Engl J Med 336 1997 404 409
11. S Vadhan-Raj C Verschraegen L McGarry Recombinant human thrombopoietin (rhTPO) attenuates high-dose carboplatin (C)-induced thrombocytopenia in patients with gynecologic malignancy Blood 90 suppl 1 1997 580a abstr 2581
12. E Archimbaud OG Ottmann JAL Yin A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia Blood 94 1999 3694 3701
13. CA Schiffer K Miller RA Larson A double blind, placebo controlled trial evaluating pegylated recombinant human megakaryocyte growth and development factor (MGDF) as an adjunct to induction and consolidation therapy in patients with acute myeloid leukemia (AML) Blood 92 suppl 1 1998 313a abstr 1283
14. L Cripe D Neuberg M Tallman A pilot study of recombinant human thrombopoietin (rhTPO) and GM-CSF following induction therapy in patients older than 55 years with acute myeloid leukemia (AMI) Blood 92 suppl 1 1998 616a abstr 2539
15. R Beveridge M Schuster E Waller Randomized, double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients (Pts) following autologous bone marrow transplantation (ABMT) Blood 90 suppl 1 1997 580a abstr 2580
16. B Bolwell J Vredenburgh B Overmoyer Safety and biologic effect of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients following autologous peripheral blood progenitor cell transplantation (PBPC) Blood 90 suppl 1 1997 171a abstr 756
17. R Nash R Kurzrock J DiPersio Safety and activity of recombinant human thrombopoietin (rhTPO) in patients (pts) with delayed platelet recovery (DPR) Blood 90 suppl 1 1997 262a abstr 1151
18. G Somlo I Sniecinski A ter Veer Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy Blood 93 1999 2798 2806
19. J Gajewski M Korbling M Donato Recombinant human thrombopoietin (rhTPO) for mobilization of peripheral blood progenitor cells (PBPC) for autologous transplantation in breast cancer: Preliminary results of a phase I trial Blood 90 suppl 1 1997 97a abstr 427
20. C Linker P Anderlini R Herzig A randomized, placebo-controlled, phase II trial of recombinant human thrombopoietin (rhTPO) in subjects undergoing high dose chemotherapy (HDC) and PBPC transplant Blood 92 suppl 1 1998 682a abstr
21. SH Bernstein AP Nademanee JM Vose A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation Blood 91 1998 3509 3517